Q-omics provides the consensus-scored PLA2G4C profile across patient tissues and cancer cell-line models. PLA2G4C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLA2G4C is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, PLA2G4C protein abundance shows 20,761 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where PLA2G4C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G4C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G4C survival associations across molecular data types. PLA2G4C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G4C RNA expression–survival associations across cancer types. High PLA2G4C expression shows unfavorable associations in UVM, THYM and MESO, but favorable associations in HNSC, ACC and SARC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PLA2G4C RNA expression.
This table summarizes PLA2G4C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G4C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G4C shows lower tumor expression in BLCA, LUSC, LUAD and UCEC and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher PLA2G4C RNA expression in normal versus tumor tissue (log2 FC = −1.825, t-test p < 0.001).
This table shows molecular features associated with PLA2G4C in patient tissues and cancer cell lines. In patient samples, PLA2G4C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G4C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
